Asitia
Conditions
Interventions
Experimental Group:For patients who were allowed to eat freely after general surgery, oral bismuth was administered starting from the day of free eating and the intervention lasted for 3 days.
Control group:Patients who are free to eat after general surgery are given routine care and treatment, and no bismuth agent intervention is provided.
Sponsors
The Second Affiliated Hospital of Kunming Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age: 18 years old and above, gender not restricted. 2. Post-operative status: Patients who can resume normal eating after general surgery, without acute complications or organ dysfunction. 3. Appetite score: The appetite score is <=6 points (based on the visual analogue scale), meeting the initial screening criteria for studying appetite changes. 4. Normal acute inflammatory indicators: The patient's acute inflammatory indicators (such as CRP, IL-6, TNF-a, etc.) are all within the normal range, ensuring that they are not in an acute inflammatory state. 5. Informed consent: Able to understand the purpose and content of the study and willing to sign the informed consent form to participate in this research. 6. Autonomous eating ability: The patient can eat independently and cooperate with the study.
Exclusion criteria
Exclusion criteria: 1. Acute inflammation: During the study period, the acute inflammatory indicators such as CRP, IL-6, and TNF-a exceeded the normal range, or there were systemic inflammatory diseases (such as sepsis, acute pancreatitis, etc.). 2. Gastrointestinal diseases: Patients with symptoms such as gastrointestinal bleeding, intestinal obstruction, and acute abdominal pain during the study period. 3. Immunosuppression or immune system diseases: Such as long-term use of immunosuppressive drugs, or having autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, etc.). 4. Major organ dysfunction: Patients with impaired functions of important organs such as the liver, kidneys, heart, and lungs. 5. Pregnant or lactating women: Because bismuth preparations may have an impact on the fetus or infant. 6. Patients unable to comply with the study requirements: Such as patients with cognitive impairment or mental illness who cannot cooperate with the study. 7. No endocrine diseases affecting food intake such as diabetes or thyroid dysfunction. 8. Patients allergic to bismuth preparations or other study drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in appetite;Changes in GLP-1 levels;Clinical symptoms: Monitor the adverse reactions of patients during the intervention period, record the side effects of drugs and compliance; | — |
Countries
China
Contacts
Public ContactYanbo Sun
The Second Affiliated Hospital of Kunming Medical University
Outcome results
None listed